Engineered immune cells take aim at childhood cancer
NCT ID NCT05990751
First seen Apr 25, 2026 · Last updated Apr 25, 2026
Summary
This early-stage trial tests a new treatment called GD2 CAR T cells in children aged 1 to 16 with neuroblastoma that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them to recognize and attack the cancer, and giving them back. The main goals are to see if the cells can be made safely and to check for serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Great Ormond Street Hospital
London, United Kingdom
Conditions
Explore the condition pages connected to this study.